News > Bharat Biotech announces phase 3 results of Covaxin, says it demonstrates interim clinical efficacy of 81%

Bharat Biotech announces phase 3 results of Covaxin, says it demonstrates interim clinical efficacy of 81%

Covaxin is 81 percent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.

Interim analysis also showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups, Bharat Biotech said.